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In Marseille in 2013, extensively drug-resistant tuberculosis
clone Beijing [1] and Clostridium difﬁcile O27 [2] were the most
common causes of severe emerging infectious diseases: nine
patients died. No patients infected with the most feared and
publicized pneumonic viruses (except the well-known H1N1,
H3N2, respiratory syncytial virus and rhinovirus) have been
hospitalized in Marseilles during the past 10 years. This
discrepancy between media reports and clinical practice leads
to a reﬂection on what is real and what is predicted or
publicized among emerging infections.
Following the emergence of new respiratory viral infections,
there has been in recent years an explosion of publications in
the best medical and scientiﬁc journals based on the fear of
another catastrophic outbreak equivalent to ‘Spanish ﬂu’. This
fear started with the arrival of severe acute respiratory
syndrome (SARS) [3] from China. The reservoir for the SARS
coronavirus seemed to be bats. The evolution of disease is still
poorly understood because the epidemic started with a period
of apparent contagiousness in Hong Kong but its eventual
disappearance occurred without anyone really understanding
the reasons why the outbreak petered out. Worldwide, there
were 8096 SARS cases, including 774 deaths [3]. There was
only one case in France. Based on ISI-Thomson-Reuters data,
there are 8943 publications with the keyword SARS (more
than 12 per death) and 146 235 citations. H5N1 avian ﬂu was
then the subject of widespread concern in the media, and
much activity in scientiﬁc journals and at WHO. It justiﬁed the
establishment of human vaccines while evidence of inter-hu-
man transmission remained extremely low. In terms of human
disease, the risk of H5N1 remains low with 615 cases
recorded and 362 deaths (mainly in Indonesia, Egypt and
Vietnam) [4]. Despite this, there have been since 2005, 6748
publications and 64 729 citations (source ISI-web October
2013)—a ratio of 20 publications per death. The disease has
remained a zoonosis with regional circulation; there has been
no case in France.
This reactivity and fear vis-a-vis emerging viruses shows no
sign of abating. Hence, for the new avian inﬂuenza H7N9 there
have been 180 publications in 2013, based on 135 cases
including 44 deaths (in China and Taiwan) [5–8], or a ratio of
four papers per death. There has been no case in France. The
new coronavirus emerging in the Middle East has generated
142 publications during the year 2013, although only 138 cases
have been reported with 60 deaths (mainly in Saudi Arabia) [9–
12]. This is a ratio of 2.4 publications per death. There have
been two cases in France. In total, these four viral respiratory
infections have generated a number of publications that is
disproportionate to the public health problem.
By contrast—for example—this year in India there has been
an outbreak of acute encephalitis syndrome (probably caused
by Japanese encephalitis virus, but other factors may be
involved) that has caused around 1200 deaths (http://www.
ﬂutrackers.com/forum/showthread.php?p=514124), but has
been the subject of just six publications (data from Scopus
Nov 13, 2013), or 0.005 publications per death. Moreover,
tuberculosis kills around 1.4 million people worldwide each
year, with the extensively drug-resistant form causing partic-
ular concern. The emerging epidemic Beijing clone (856
publications, 1596 citations) caused at least 13% (180 000) of
tuberculosis deaths [13]. That is a true emerging killer!
Emerging Clostridium difﬁcile clone O27 (477 publications, 7980
citations) has received much less attention than SARS, despite
the reality of a worldwide pandemic that has killed thousands
of people, with a case fatality rate of 30%. It has killed at least
200 people in France [14] and causes a signiﬁcant proportion
of the 14 000 C. difﬁcile deaths per year in the USA reported
by the CDC, which have multiplied threefold during the past
10 years. A comparable ﬁgure is observed in Europe (E.J.
Kuijper, personal communication).
It is our duty as medical journals to report ongoing and
emerging outbreaks, but to try to avoid disproportionate
reactions that ultimately inﬂuence governments and interna-
tional agencies, and lead to costly control strategies that are of
questionable value including from the scientiﬁc community.
The main reason we do not publish more on the “real”
epidemics is that we are not sent the papers. What does this
over-representation of emerging viral agents of pneumonias
reﬂect? Is it people’s fear of the unknown, the power of the
involved scientists, or perhaps the ﬁnancial interest of the
vaccine and pharmaceutical industries? Modelling of outbreaks,
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by considering the most catastrophic scenarios, might also lead
to a disproportionate response despite its repeated failure to
give accurate predictions [15]. We should not confuse
prediction and reality: for the moment the new respiratory
viruses have been ‘much ado about nothing’.
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